Autoimmune gastritis

Summary

Autoimmune gastritis (MONDO:0031014) is a disease and 6 clinical trials. Top therapeutic interventions include betaine, hydrogen, and glycinebetaine. A subtype of autoimmune disorder of gastrointestinal tract — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	autoimmune gastritis
Mondo ID	MONDO:0031014
DOID	DOID:0040090
ICD-11	248006617
NCIT	C95752
UMLS	C3887639
MedGen	854482
Is cancer (heuristic)	no

Also known as: autoimmune gastritis (disease)

Disease family

This is a subtype of autoimmune disorder of gastrointestinal tract. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › autoimmune disorder of gastrointestinal tract › autoimmune gastritis

Related subtypes (6): celiac disease, type 1 diabetes mellitus, autoimmune pancreatitis, autoimmune hepatitis, IgG4-related sclerosing cholangitis, autoimmune enteropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05021029	Not specified	ENROLLING_BY_INVITATION	UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study
NCT06272500	Not specified	RECRUITING	Safety and Efficacy Study of Betaine Hydrochloride in Treating Hypergastrinemia in Patients With Autoimmune Gastritis
NCT06557252	Not specified	NOT_YET_RECRUITING	The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG
NCT06881511	Not specified	RECRUITING	Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
NCT06946706	Not specified	RECRUITING	Assessing the Prevalence and Epidemiological Characteristics of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Autoimmune Gastritis(AIG) Through Hydrogen and Methane Breath Testing(HMBT).
NCT05820607	Not specified	UNKNOWN	Clinical Characteristics, Lifestyle and Multi-omics Analysis in Autoimmune Gastritis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BETAINE	4	3
HYDROGEN	2	1
GLYCINEBETAINE	0	1